Pacific Biosciences of California, Inc.
PACB
$1.14
-$0.03-2.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 39.22M | 39.97M | 36.01M | 38.81M | 58.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.22M | 39.97M | 36.01M | 38.81M | 58.36M |
| Cost of Revenue | 31.35M | 26.76M | 21.85M | 26.19M | 43.92M |
| Gross Profit | 7.88M | 13.21M | 14.16M | 12.63M | 14.44M |
| SG&A Expenses | 56.04M | 36.85M | 38.38M | 43.75M | 46.00M |
| Depreciation & Amortization | 6.85M | 6.85M | 6.85M | 6.85M | 6.85M |
| Other Operating Expenses | 998.00K | -- | -- | -- | 3.44M |
| Total Operating Expenses | 128.60M | 95.97M | 99.66M | 120.24M | 144.74M |
| Operating Income | -89.38M | -56.01M | -63.65M | -81.43M | -86.39M |
| Income Before Tax | 2.69M | -60.73M | -173.32M | -78.18M | -82.74M |
| Income Tax Expenses | 316.00K | -- | -- | -- | -718.00K |
| Earnings from Continuing Operations | 2.37M | -60.73M | -173.32M | -78.18M | -82.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.37M | -60.73M | -173.32M | -78.18M | -82.02M |
| EBIT | -89.38M | -56.01M | -63.65M | -81.43M | -86.39M |
| EBITDA | -79.68M | -44.96M | -53.30M | -71.34M | -76.56M |
| EPS Basic | 0.01 | -0.22 | -0.64 | -0.29 | -0.31 |
| Normalized Basic EPS | -0.20 | -0.12 | -0.14 | -0.19 | -0.20 |
| EPS Diluted | 0.01 | -0.22 | -0.64 | -0.29 | -0.31 |
| Normalized Diluted EPS | -0.18 | -0.12 | -0.14 | -0.19 | -0.20 |
| Average Basic Shares Outstanding | 283.00M | 272.92M | 272.39M | 269.58M | 267.12M |
| Average Diluted Shares Outstanding | 306.89M | 272.92M | 272.39M | 269.58M | 267.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |